Ki67, CD105 and α-smooth muscle actin expression in disease progression model of oral submucous fibrosis

• Published in: Journal of investigative and clinical dentistry Vol. 10; no. 4; p. e12443
• Main Authors: Gadbail, Amol R, Chaudhary, Minal S, Sarode, Sachin C, Gondivkar, Shailesh M, Belekar, Lalita, Mankar-Gadbail, Mugdha P, Dande, Ravi, Tekade, Satyajit A, Yuwanati, Monal B, Patil, Shankargouda
• Format: Journal Article
• Language: English
• Published: Australia 01.11.2019
• Subjects: Actins; Biomarkers, Tumor; Carcinoma, Squamous Cell; Disease Progression; Humans; Ki-67 Antigen; Mouth Neoplasms; Muscle, Smooth; Oral Submucous Fibrosis; oral submucous fibrosis; α-smooth muscle actin; CD105; oral squamous cell carcinoma; Ki67
• ISSN: 2041-1626
• DOI: 10.1111/jicd.12443

The aim of this study was to investigate the expression of Ki67, CD105 and α-smooth muscle actin (α-SMA) expression in oral submucous fibrosis (OSF) and oral squamous cell carcinoma in the background of OSF (OSCC-SMF). The study was carried out on paraffin-embedded tissues of 30 normal oral mucosa (NOM), 50 OSF cases and 105 OSCC-SMF. The immunohistochemistry was carried out to evaluate the expression of Ki67, CD105 and α-SMA antigen. Ki67 labelling index (LI), CD105 and α-SMA expression showed increasing trend from NOM, low-risk epithelial dysplasia (LRED), high-risk epithelial dysplasia (HRED), well-differentiated squamous cell carcinoma (WDSCC), moderately differentiated squamous cell carcinoma to poorly differentiated squamous cell carcinoma. However, there was no significant difference of α-SMA expression between HRED and WDSCC. In OSCC-SMF, Ki67 LI, CD105 and α-SMA were significantly higher in advanced clinical TNM stage, metastasis and less than 3 years patient survival as compared with early clinical TNM stage, non-metastasis and 3 years or more patient survival. Ki67 LI, α-SMA and CD105 expression alone or together correspond with the disease progression model of SMF. Hence, expression of these markers can be used as a predictive marker of clinical outcome of OSCC-SMF.